Gemini Therapeutics (GMTX) Competitors $50.08 +0.40 (+0.80%) As of 05/20/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrendsBuy This Stock GMTX vs. BBIO, BPMC, ELAN, LEGN, TLX, VRNA, LNTH, TGTX, GRFS, and AXSMShould you be buying Gemini Therapeutics stock or one of its competitors? The main competitors of Gemini Therapeutics include BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), Legend Biotech (LEGN), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Verona Pharma (VRNA), Lantheus (LNTH), TG Therapeutics (TGTX), Grifols (GRFS), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. Gemini Therapeutics vs. BridgeBio Pharma Blueprint Medicines Elanco Animal Health Legend Biotech Telix Pharmaceuticals Limited American Depositary Shares Verona Pharma Lantheus TG Therapeutics Grifols Axsome Therapeutics Gemini Therapeutics (NASDAQ:GMTX) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, risk, valuation, analyst recommendations, dividends, earnings and profitability. Does the MarketBeat Community prefer GMTX or BBIO? BridgeBio Pharma received 160 more outperform votes than Gemini Therapeutics when rated by MarketBeat users. Likewise, 72.47% of users gave BridgeBio Pharma an outperform vote while only 63.33% of users gave Gemini Therapeutics an outperform vote. CompanyUnderperformOutperformGemini TherapeuticsOutperform Votes1963.33% Underperform Votes1136.67% BridgeBio PharmaOutperform Votes17972.47% Underperform Votes6827.53% Does the media refer more to GMTX or BBIO? In the previous week, BridgeBio Pharma had 12 more articles in the media than Gemini Therapeutics. MarketBeat recorded 12 mentions for BridgeBio Pharma and 0 mentions for Gemini Therapeutics. BridgeBio Pharma's average media sentiment score of 0.80 beat Gemini Therapeutics' score of 0.00 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Overall Sentiment Gemini Therapeutics Neutral BridgeBio Pharma Positive Do analysts rate GMTX or BBIO? BridgeBio Pharma has a consensus price target of $57.09, suggesting a potential upside of 73.85%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00BridgeBio Pharma 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92 Which has more volatility and risk, GMTX or BBIO? Gemini Therapeutics has a beta of -0.12, suggesting that its stock price is 112% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Do insiders & institutionals have more ownership in GMTX or BBIO? 75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by insiders. Comparatively, 18.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is GMTX or BBIO more profitable? Gemini Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -241.44%. BridgeBio Pharma's return on equity of 0.00% beat Gemini Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gemini TherapeuticsN/A -38.78% -35.88% BridgeBio Pharma -241.44%N/A -75.69% Which has better valuation & earnings, GMTX or BBIO? Gemini Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. Gemini Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGemini TherapeuticsN/AN/A-$71.87M-$1.00-50.08BridgeBio Pharma$127.42M48.94-$535.76M-$3.53-9.30 SummaryBridgeBio Pharma beats Gemini Therapeutics on 13 of the 17 factors compared between the two stocks. Get Gemini Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GMTX vs. The Competition Export to ExcelMetricGemini TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.17B$6.53B$5.38B$8.39BDividend YieldN/A2.64%5.21%4.10%P/E Ratio-50.088.9226.7619.71Price / SalesN/A252.24389.71117.54Price / CashN/A65.8538.2534.62Price / Book17.336.466.784.50Net Income-$71.87M$143.98M$3.23B$248.18M7 Day Performance9.51%2.03%1.51%0.23%1 Month Performance19.07%4.11%10.03%12.39%1 Year Performance60.20%-2.87%16.65%7.07% Gemini Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GMTXGemini TherapeuticsN/A$50.08+0.8%N/A+54.7%$2.17BN/A-50.0830BBIOBridgeBio Pharma4.5992 of 5 stars$35.68+4.4%$57.09+60.0%+12.2%$6.77B$127.42M-12.52400Insider TradeBPMCBlueprint Medicines1.7871 of 5 stars$100.31+3.2%$126.56+26.2%-2.0%$6.48B$562.12M-92.88640Positive NewsInsider TradeELANElanco Animal Health3.2174 of 5 stars$12.82+7.2%$15.00+17.0%-24.4%$6.36B$4.43B32.049,800Positive NewsAnalyst ForecastLEGNLegend Biotech3.5317 of 5 stars$32.38+1.9%$78.82+143.4%-34.1%$5.95B$627.24M-34.081,070News CoverageAnalyst RevisionGap UpTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.25-5.4%$22.00+35.4%N/A$5.49B$783.21M0.00N/APositive NewsVRNAVerona Pharma2.672 of 5 stars$67.53+6.6%$81.50+20.7%+492.7%$5.48B$118.54M-35.1730Positive NewsGap DownLNTHLantheus4.4526 of 5 stars$79.52-2.7%$132.67+66.8%-6.9%$5.45B$1.54B13.23700Positive NewsHigh Trading VolumeTGTXTG Therapeutics3.8231 of 5 stars$34.99+4.0%$40.80+16.6%+106.0%$5.34B$386.39M-349.87290Positive NewsGRFSGrifols3.0009 of 5 stars$7.73+8.9%N/A+6.8%$5.31B$7.21B6.6126,300AXSMAxsome Therapeutics4.7189 of 5 stars$110.16+2.2%$172.14+56.3%+35.4%$5.31B$432.16M-18.39380Positive NewsInsider Trade Related Companies and Tools Related Companies BridgeBio Pharma Alternatives Blueprint Medicines Alternatives Elanco Animal Health Alternatives Legend Biotech Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives Verona Pharma Alternatives Lantheus Alternatives TG Therapeutics Alternatives Grifols Alternatives Axsome Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GMTX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump + Musk = AI’s turning pointTrump may not code… but he knows how to pick winners. And according to insiders, his administration is prep...True Market Insiders | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemini Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemini Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GMTX Stock Free GMTX Stock Alerts